Compare BLDR & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLDR | CORT |
|---|---|---|
| Founded | 1998 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | RETAIL: Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8B | 7.6B |
| IPO Year | 2005 | 2001 |
| Metric | BLDR | CORT |
|---|---|---|
| Price | $55.48 | $64.83 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 24 | 5 |
| Target Price | $67.50 | ★ $142.60 |
| AVG Volume (30 Days) | ★ 2.4M | 1.2M |
| Earning Date | 10-29-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.08 | ★ 1.13 |
| Revenue | ★ $15,190,638,000.00 | $761,407,000.00 |
| Revenue This Year | N/A | $52.09 |
| Revenue Next Year | N/A | $44.73 |
| P/E Ratio | $716.13 | ★ $59.79 |
| Revenue Growth | N/A | ★ 12.79 |
| 52 Week Low | $49.67 | $28.66 |
| 52 Week High | $131.50 | $126.38 |
| Indicator | BLDR | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 41.73 | 21.65 |
| Support Level | $49.67 | $30.24 |
| Resistance Level | $78.13 | $122.93 |
| Average True Range (ATR) | 3.22 | 4.81 |
| MACD | -0.89 | -0.10 |
| Stochastic Oscillator | 0.30 | 2.23 |
Builders FirstSource Inc is a manufacturer and supplier of building materials. The company offers structural and related building products such as factory-built roof and floor trusses, wall panels and stairs, vinyl windows, custom millwork and trim, and engineered wood. The products can be designed for each home individually and are installed by Builders FirstSource. The company's construction-related services include professional installation, turn-key framing, and shell construction. Builders FirstSource's customers range from large production builders to small custom homebuilders.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.